$4bn collaboration sees Abpro expand its global capabilities

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/immunotherapy)
(Image: Getty/immunotherapy)

Related tags: multi-specific antibodies, Immuno-oncology, Immunotherapy, T cell, T cell receptor, T cells

Abpro and NJCTTQ enter $4bn agreement to develop bispecific antibody therapies for immuno-oncology and extend its global reach.

Per the agreement, NJCTTQ may pay Abpro up to $4bn (€3.5bn), including $60m in research and development funding, milestones and royalties. Abpro will retain all commercial rights for any approved molecules outside of China and Thailand. China-based NCTTQ will hold the rights to approved molecules in China.

Both companies will collaborate globally to pursue pre-clinical and clinical development, and commercialization.

“Our ex-China commercial rights have the potential to generate significant long-term value for our company. We intend to pursue additional similar development collaborations that leverage our innovative technology platforms and programs that include commercial rights in key global markets,”​ Ian Chan, executive chairman and co-founder of Abpro said in a statement.

According to Abpro, NJCTTQ has a pipeline that is “highly complementary”​ to that of Abpro’s immuno-oncology development platforms.

NJCTTQ will use Abpro’s immuno-oncology platforms, DiversImmune and Multimab. According to the company, DiversImmune has generated antibodies against more than 300 targets, and Mulitmab enables the assembly of antibodies into a variety of bi- and multi-specific antibody formats.

Using the platforms, Abpro has developed a pipeline of seven immuno-oncology therapeutic candidates, including T-cell engagers.

Abpro was unable to respond to our request for comment. 

Related news

Follow us

Products

View more

Webinars